ResoSphere resorbable embolic microsphere technology
Embolization and Resorbable Particles?
Arterial embolization is the selective blocking of arteries by purposely introducing emboli, or foreign bodies that block blood flow. Embolization is a minimally invasive procedure involving only a small slit in the skin.
In arterial embolization, the doctor threads a catheter into the artery that needs to be closed off. At this point, the embolic agents are introduced into the vessel and occludes the artery.
Arterial embolization is used to treat aneurysms, bleeding, AVMs, uterine fibroids, and some types of cancer to mention a few indications. When a tumor is being fed by an artery, arterial embolization can be used to cut off the tumor’s nutrient supply resulting in tumor cell death.
Transarterial chemoembolization (TACE) involves the emulsification of a chemotherapeutic agent in a viscous Drug carrier, delivered intra-arterially to the tumor for maximum effect. TACE reduces arterial inflow, diminishes washout of the chemotherapeutic agent, and decreases systemic exposure.
The current microsphere market leaders use non-bioresorbable materials and remain in the vessels indefinitely. Permanent material may cause chronic inflammatory reaction in the treated area. University of Minnesota researchers have developed bioresorbable microspheres that can be absorbed by the body after the therapeutic treatment has been obtained.
Bioresorbable Embolic Beads
A new bioresorbable embolic bead technology blocks blood vessels supplying tumors without causing long term blockage of the blood vessels of healthy tissue. These bioresorbable embolic beads offer the potential for controlled and predictable drug release and bead absorbtion. This embolic beads are microspheres made of materials that serve as drug delivery capsules. Evaluation has shown that the length of time for these beads to degrade can be controlled and designed into the material with predictability for specific applications. After the microsphere has delivered its agent, it will continue to function as a local embolic agent, denying the tumor of blood supply for the duration of time designed into the material. These beads degrade at a controlled rate and are eventually reabsorbed by the body. This allows them to serve as embolic agents, but does not cause permanent occlusion in blood vessels supplying healthy tissue and may allow for better restoration of artery integrity after embolization compared to non-bioresorbable microspheres.
EmboMedics was formed to further develop and commercialize the technology.
“The future outlook of embolic particles is dependent on the development of something revolutionary.
Most patients do not like the idea of having a foreign object in their body permanently. Resorbable embolic particles [are] the future of embolic product development. If the embolic particle could be designed to be resorbable over time once the [indication] is treated with occlusion that would be ideal.”
– Interventional Radiologist, US
“A new paradigm for embolization has recently appeared and is called resorbable embolics.
While it is believed that to destroy a benign or malignant tumor a permanent embolization is needed, more and more concern is raised on permanent occlusion of the parent artery.
In fact, not only the idea to leave foreign body in the patient is a matter of concern, also the inability to return to the lesion through the same arterial route can be a concern in case of relapse of the tumor.One could easily make the parallel with the ongoing revolution of bioresorbable stent (scaffolding) that will in the near future replace permanent metallic stent into the coronaries.”
-Marc R. Sapoval, M.D., Ph.D- Professor of clinical radiology and chair of the cardiovascular radiology department at Hôpital Européen Georges-Pompidou-Paris
“Drug Eluting Beads are seen as the incoming standard-of-care, at least for HCC. The vast majority of our primary liver cancer patients are treated with DEBs now.”
– Interventional Radiologist, US
“With an embolic agent that can disappear after the effect has been achieved, then it would be irresponsible not to use that embolic agent.”
– Gary Siskin, MD,
Professor and Chairman, Department of Radiology, Albany Medical Center, Albany, New York
GEST – May 2014